Secreted-frizzled related proteins (SFRPs) are modulators of the Wnt signaling pathway which is closely involved in normal and malignant hematopoiesis. Epigenetic deregulation of Wnt modulators leading to aberrant signaling has been demonstrated in adult acute myeloid leukemia (AML) patients but its occurrence in childhood AML patients and the role of individual modulators are unclear. In this study, we examined SFRP1, SFRP2, SFRP4, and SFRP5 promoter methylation in 83 AML patients (59 children and 24 adults) and found preferential SFRP1 methylation and mRNA downregulation in the prognostically favorable subgroup of AML with t(8;21) translocation. Among the four genes, SFRP1 methylation independently predicted prolonged event-free and relapse-free survivals in childhood non-acute promyelocytic leukemia patients with non-adverse cytogenetics. Mechanistically, we further demonstrated that RUNX1-ETO, the t(8;21) fusion product, specifically bound the SFRP1 promoter and repressed its transcription via a consensus RUNX binding site. In t(8;21)-leukemia cells, SFRP1 selectively inhibited canonical Wnt signaling and cellular proliferation that were associated with concomitant downregulation of Wnt/β-catenin target genes including CCND1 and MYC. Taken together, we identified SFRP1 as a transcriptional repression target of the t(8;21) fusion protein and demonstrated a novel mechanism of Wnt activation in a specific subtype of AML.
Introduction
The Wnt signaling pathway is an important regulator of hematopoietic cell fate and growth. 1, 2 Deregulation of this pathway has been implicated in human leukemogenesis. 3 Wnt signaling comprises the canonical pathway with β-catenin as a central mediator and noncanonical pathways primarily involving Ca 2+ ions and planar cell polarity. 4 Signal transduction by Wnts is tightly regulated by several families of extracellular modulators, among which secreted frizzled-related proteins (SFRPs) are the largest family. 4 SFRPs are generally regarded as Wnt antagonists. However, they can also activate Wnt signaling and interfere with other signaling pathways through Wnt-independent mechanisms. 4 In humans, five SFRP genes (SFRP1, SFRP2, SFRP3, SFRP4, and SFRP5) have been identified and four of these genes except SFRP3 contain dense CpG islands around their promoter regions. Interestingly, previous studies revealed that SFRP1, SFRP2, SFRP4, SFRP5 and other Wnt modulators were silenced by promoter hypermethylation in different cancers including acute myeloid leukemia (AML) and this epigenetic silencing was associated with aberrant Wnt activation. [5] [6] [7] [8] Moreover, in AML, the Wnt signaling can also be activated by mutant fms-like tyrosine kinase 3 (FLT3) and common translocation-associated fusion proteins. 9, 10 Collectively, these findings indicate that Wnt signaling aberration involves multiple mechanisms and is a common molecular feature in different biological subtypes of AML.
t(8;21)(q22;q22) is the most frequent karyotypic abnormality in AML, representing about 15% of total cases, and is associated with the French-American-British (FAB) M2 subtype. 
RUNX1-ETO has
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From been postulated as a dominant RUNX1 inhibitor because it represses genes that are activated by RUNX1. 12, 13 Moreover, RUNX1-ETO can recruit multiple corepressors and chromatin remodeling proteins including histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) to induce heterochromatic gene silencing, 14, 15 rendering the fusion protein a potent transcriptional repressor. On the other hand, RUNX1-ETO can also activate gene transcription. 16, 17 In particular, the fusion protein has been demonstrated to induce plakoglobin expression and activate the Wnt/β-catenin pathway in hematopoietic cells. 10 These findings provided evidence for a causal link between t(8;21) and aberrant Wnt signaling in AML pathogenesis.
Previous studies revealed that SFRP promoter methylation might carry prognostic implications in adult AML patients. 6, 7, 18 Nonetheless, since there is growing evidence indicating biologic heterogeneity between adult and childhood AML patients, 19 whether SFRP methylation also occurs in childhood AML patients and carries prognostic impacts is unknown. Moreover, the role of individual SFRP genes in AML still remains unclear. In this study, we found specific association of SFRP methylation with distinct cytogenetic subtypes in childhood AML patients and that SFRP1 methylation was an independent prognostic factor for survivals in a subset of these patients. Further mechanistic studies indicated that SFRP1 was a transcriptional repression target of the RUNX1-ETO protein and this repression promoted canonical Wnt signaling and cell proliferation of t(8;21)-leukemia cells. These findings uncover an additional mechanism by which RUNX1-ETO perturbs the Wnt pathway and contributes to t(8;21) leukemogenesis.
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Materials and methods

Patient samples and cell culture
All patients' BM samples were subjected to Ficoll-Hypaque centrifugation and mononuclear cells were stored at -80°C before use.
Suspension cell lines (Kasumi-1, THP-1, MV4-11, CMK, NB4, ME-1, and U937) were Zhang (Department of Pathology, University of California, San Diego, CA). Cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA). For U937T and U937T-AE, the medium contained 1μg/ml tetracycline (Invitrogen) for RUNX1-ETO repression.
Sodium bisulfite modification and methylation-specific PCR (MSP)
Bisulfite-modified DNA was prepared using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA). SFRP1, SFRP2, SFRP4, and SFRP5 methylation was examined by MSP using primers described before. 22, 23 For SFRP4, primers were designed using MethPrimer. 24 Primer sequences and PCR conditions were provided in Supplemental data (Table S1 ).
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RNA extraction and real-time RT-PCR
Total RNA was extracted using TRIZOL (Invitrogen) and treated with DNaseI (USB, Cleveland, OH). Real-time RT-PCR analysis of gene expression was performed using Power SYBR Green PCR Master Mix (ABI, Foster City, CA) and normalized to GAPDH. Samples were amplified for 40 cycles of 30 seconds at 95°C and 30 seconds at 62°C. Relative expression levels were determined by the 2 -ΔΔCt method unless otherwise stated. Primer sequences were listed in Table S1 .
Detection of RUNX1-ETO fusion transcripts was done as described. 25 Expression profiling of Wnt signaling genes was performed using the Human Wnt Signaling Pathway RT Table S1 . School of Medicine, Nashville, TN). pCMV-RUNX1-ETOΔ469 and mutant SFRP1 promoter construct were prepared as previously described. 25 Human SFRP1 cDNA expression plasmid (pCMV-SFRP1) was obtained from Origene (Rockville, MD). T-cell factor/lymphoid enhancerbinding factor (TCF/LEF), activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT) firefly luciferase reporters were obtained from SABiosciences.
Transient transfection was performed using Lipofectamine 2000 (Invitrogen) as previously described. 25 For HeLa, cells were transfected with 0.5μg SFRP promoter constructs, 1μg pCMV expression plasmids, and 6.25ng Renilla luciferase plasmid pRL-CMV (Promega).
For U937, U937T and U937T-AE, cells were transfected with 1.5μg SFRP1 promoter constructs and 1μg pRL-CMV in the presence or absence of 1.5μg pCMV expression plasmids. For TCF/LEF, AP-1 and NFAT reporter studies, cells were transfected with 1μg luciferase reporters and 0.5μg pCMV expression plasmids. Luciferase activity was measured 24 hours after transfection unless otherwise stated.
To examine the effect of RUNX1-ETO on endogenous SFRP1 expression, we transiently transfected A549 lung cancer cells with 10μg of pCMV-RUNX1-ETO using Lipofectamine 2000 as previously described. 25 SFRP mRNA levels were examined by real-time RT-PCR 48 hours after transfection. 
Western blot analysis
Nuclear and whole cell lysates were prepared as previously described. 
Measurement of phospho-Jun N-terminal kinase (JNK) and phospho-p38 mitogen-activated protein kinase (MAPK)
Flow cytometric analysis of phospho-JNK and phospho-p38 MAPK was performed as previously described. 28 Briefly, cells were fixed in 1.5% formaldehyde and permeabilized with methanol. Cells were then incubated with rabbit monoclonal phospho-JNK and phospho-p38
MAPK antibodies (Cell Signaling Technology), followed by goat anti-rabbit IgG Alexa Fluor 488-labeled secondary antibody (Invitrogen). Stained cells were analyzed by a FACSCalibur flow cytometer (BD Biosciences, Rockville, MD).
Measurement of cell proliferation
Cells were treated with the indicated concentrations of recombinant SFRP1 or SFRP4
proteins (R&D systems, Minneapolis, MN) for the indicated time period. Cell proliferation was measured using the WST-1 Cell Proliferation Reagent (Roche Applied Science, Indianapolis, IN).
Data analysis
Unpaired t and Fisher's exact tests were used to analyze the relationship with continuous and categorical variables between groups. Complete survival data were available from 58 childhood AML patients. Patients with APL (n=7) were excluded for survival analysis. Eventfree survival (EFS), relapse-free survival (RFS), and overall survival (OS) were analyzed using the Kaplan-Meier method and survival curves were compared by the log-rank test. EFS was measured from the date of diagnosis until failure to achieve CR, relapse, or death from any cause (whichever occurred first), censoring for those alive and event-free at last follow-up. RFS was measured from the date of achievement of CR until relapse or death from any cause (whichever occurred first), censoring for those alive and relapse-free at last follow-up. OS was measured from the date of diagnosis until death from any cause, censoring for those alive at last follow-up.
Cox regression analysis was performed to test the significance of SFRP1 methylation after controlling for other potential prognostic factors including age, gender, presentation white blood cell (WBC) count, FAB subtype (M7 and non-M7), FLT3 mutations, KIT mutations, NPM1 mutations, CEBPA double mutations, and treatment received (4 courses, 5 courses, and allogeneic transplant). Two-sided P<0.05 were considered statistically significant. Survival analysis was performed using SPSS 13.0 (SPSS, Chicago, IL).
Results
Methylation of SFRP promoters in childhood AML patients
To verify our MSP platform, we first employed a multiple myeloma (LP1) and cervical In our cohort of 59 childhood AML patients, 36 (61%) of them did not show any SFRP promoter methylation. Among patients with SFRP methylation (n=23), 15 of them had one methylated SFRP gene, 7 patients had 2 methylated genes and 1 patient had three methylated genes ( Fig. 1C) . None of the patients showed concurrent methylation of the four SFRP promoters.
The methylation frequency of SFRP1, SFRP2, SFRP4, and SFRP5 promoter was 34% (20/59), 17% (10/59), 0% (0/59), and 3% (2/59), respectively. Aberrant SFRP1 methylation was found to be significantly associated with concurrent methylation of SFRP2 or SFRP5 promoter (P=0.005).
Clinicopathological significance of SFRP promoter methylation in childhood AML patients
To investigate the clinicopathological significance of SFRP methylation in childhood AML patients, we first compared patients who had at least one methylated SFRP gene (n=23) to those patients without any SFRP methylation (n=36) ( 
between these non-t(8;21) M2 patients (mean expression ratio=-1.49) and the t(8;21) patients (P=0.054). As expected, a significant association between SFRP1 methylation and mRNA downregulation (P=0.001) was found (Fig. 3B) . (Fig. 4B ).
Because Kasumi-1 cells also express RUNX1, we performed ChIP with anti-ETO antibody to distinguish RUNX1-ETO from wild-type RUNX1. The binding of RUNX1-ETO to this chromatin region was confirmed by the detection of ETO immunocomplexes in Kasumi-1 but not THP-1 cells (Fig. 4B) . The RUNX1-ETO protein has been demonstrated to recruit multiple transcriptional corepressors and chromatin remodeling proteins to mediate gene repression. 14, 15 We found that DNA sequences flanking the RUNX site were also immunoprecipitated by anti-HDAC1, anti-MeCP2, anti-DNMT1, and anti-DNMT3b antibodies in SFRP1-silenced Kasumi-1 but not in SFRP1-expressing THP-1 cells (Fig. 4B) . The specificity of these interactions was indicated by the failure to detect distal SFRP1 sequences lacking RUNX binding sites in the same samples (Fig. 4B, oligo 2) . Together, these findings indicate that the RUNX site on the SFRP1 promoter is a molecular target for the RUNX1-ETO fusion protein.
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To investigate the transcriptional control of the SFRP1 gene by the RUNX1-ETO protein, we cloned a 0.7-kb SFRP1 promoter fragment containing the RUNX site into pGL3-Basic and cotransfected the construct with the t(8;21) expression plasmid into U937 myeloid cells. Ectopic expression of RUNX1-ETO but not the functionally related inv(16) fusion protein CBFβ-MYH11 repressed the SFRP1 promoter (Fig. 5A) . Deletion of the C-terminal region of RUNX1-ETO (RUNX1-ETOΔ469), which is required for oligomerization and corepressor recruitment, 31 ablated the repression. We next conducted the reporter assays in U937T-AE and the parental U937T cells. The U937T-AE is a myeloid cell line inducibly expressing RUNX1-ETO in response to tetracycline withdrawal. 32 RT-PCR confirmed RUNX1-ETO induction by tetracycline withdrawal in U937T-AE but not U937T cells (Fig. 5B) . Concordant with results in U937 cells (Fig. 5A) , RUNX1-ETO induction repressed the SFRP1 promoter by 4.7-fold in U937T-AE cells, whereas only a mild change was observed in the parental U937T cells (Fig. 5B) . To identify the RUNX1-ETO response region, we performed 5'-deletion mapping on the SFRP1 promoter.
Removal of sequences from nt -706 to -239 did not affect the RUNX1-ETO effect as revealed by the persistence of 2.6-fold repression on -239-Luc (Fig. 5C ). However, further deletion to nt -176, which involved the consensus RUNX binding site, abolished the RUNX1-ETO repression ( into HeLa cells, which lack RUNX1 expression. 25 Overexpression of RUNX1 was found to have a mild effect (1.3-fold repression by RUNX1 vs 2.7-fold by RUNX1-ETO) on the SFRP1
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From promoter (data not shown). Finally, we examined whether RUNX1-ETO repressed other SFRP promoters including SFRP2 and SFRP3 promoters. The SFRP2 promoter is similar to SFRP1 promoter in that both are GC-rich while the SFRP3 promoter is non-GC-rich. Unlike the SFRP1 promoter, no consensus RUNX binding site was found in 1-kilobase DNA sequences upstream of the SFRP2 and SFRP3 coding regions. Luciferase reporter assays revealed that RUNX1-ETO did not repress SFRP2 and SFRP3 promoters, indicating SFRP1 as a specific transcriptional target of the RUNX1-ETO protein (Fig. 5C ).
We further investigated if RUNX1-ETO is able to inhibit endogenous SFRP1 expression.
The A549 lung cancer cell line that endogenously expresses both SFRP1 and SFRP5 mRNAs was selected for analysis. Using flow cytometric analysis of green fluorescent protein expression in the transfected cells, we previously demonstrated a transfection efficiency of 53% under our experimental conditions. 25 Ectopic expression of RUNX1-ETO reduced SFRP1 mRNA levels by 38% in A549 cells (P<0.05) (Fig. 5D ). In contrast, no significant change in SFRP5 mRNA levels was detected.
SFRP1 inhibited canonical Wnt signaling and cellular proliferation of t(8;21)-leukemia cells
The specific transcriptional repression of SFRP1 by RUNX1-ETO led us to investigate (Fig. 6A) . The expression profile of these Wnt signaling genes was found to be largely similar in other AML cell lines without t(8;21) (Fig. 6A) . Next, we asked whether SFRP1 modulated Wnt signaling in t(8;21)-leukemia cells. We employed the U937T-AE-Tet cells (U937T-AE cells cultured in the absence of tetracycline) to mimic t(8;21)-leukemia cells for luciferase reporter analysis because we failed to perform transfection on Kasumi-1 cells. The
U937T-AE-Tet cells also lack SFRP1 expression as revealed by RT-PCR (data not shown).
Lithium chloride (LiCl) is a specific inhibitor of glycogen synthase kinase-3β, 33 which phosphorylates β-catenin and promotes its degradation. Addition of LiCl potently activated the TCF/LEF reporter in U937T-AE-Tet cells (Fig. 6B ), indicating the presence of an intact canonical Wnt pathway. Ectopic expression of SFRP1 inhibited basal and LiCl-induced TCF/LEF reporter activity by 32% and 53%, respectively. We also examined whether SFRP1 expression had any effects on noncanonical Wnt signaling pathways. The NFAT-and AP-1-responsive luciferase reporters, which monitor the transcriptional response to activation of the noncanonical NFAT/Ca 2+ and JNK/planar cell polarity pathways, were employed for analysis.
We found no inhibition of transcriptional activity of these two reporters in U937T-AE-Tet cells when SFRP1 was ectopically expressed (Fig. 6B ). In accord with findings from reporter assays, treatment of Kasumi-1 cells with SFRP1 reduced nuclear β-catenin levels (Fig. 6C) , indicating suppression of the canonical Wnt pathway. In contrast, SFRP1 treatment had no significant effect on the activity of JNK and p38 MAPK (Fig. 6C) , the latter of which has been implicated in the noncanonical NFAT/Ca 2+ pathway. 34 protein inhibited cellular proliferation in a dose-dependent manner (Fig. 6D) . Likewise, we observed a similar reduction (36%) in proliferation of U937T-AE-Tet cells after 72-hour treatment of 500ng/ml SFRP1 (data not shown). Real-time RT-PCR analysis of a panel of 13 genes implicated in Wnt signaling and cell growth control revealed significant downregulation of MYC, CCND1 and CCND3 mRNA levels after SFRP1 treatment (Fig. 6E) . The MYC and CCND1 downregulation was also confirmed at the protein level (Fig. 6E) . In contrast, treatment with the same concentrations of recombinant SFRP4 protein had no significant effects on proliferation of Kasumi-1 cells, which endogenously express SFRP4. As a control, we conducted similar experiments in another AML cell line THP-1, which expresses both SFRP1 and SFRP4.
Treatment with recombinant SFRP1 or SFRP4 protein did not affect THP-1 cell proliferation (Fig. 6D) .
Discussion
Previous studies showed that promoter methylation of SFRPs and other Wnt modulators carried prognostic implications in adult AML patients. 6, 7, 18 Our present study together with those done by other groups strongly suggested that promoter methylation of Wnt modulators was associated with distinct cytogenetic subtypes of AML. Here we found that SFRP1 methylation was associated with t(8;21) and SFRP2 methylation with a normal karyotype in childhood AML. Concordantly, SFRP2 methylation was significantly associated with CEBPA double mutations, which were also found predominantly in cytogenetically-normal childhood AML patients. 36 Similar in adult AML patients, 6 we did not observe SFRP methylation in all the seven childhood APL patients. Likewise, it was reported that DKK1 promoter was preferentially methylated in CBF-AML but not in APL patients. 37 In contrast, methylation of WIF1 promoter was only found in APL patients but not in other AML subtypes. 38 Together, these observations were consistent with the recent DNA methylation microarray data showing that different biologically distinct AML subtypes were associated with specific methylation signatures. 39 In line with this, we observed that among the twelve childhood non-t(8;21) AML patients with SFRP1 methylation, eight of them showed concurrent methylation of the SFRP2 promoter. In sharp contrast, none of the eight SFRP1-methylated t(8;21) patients showed concurrent methylation of additional SFRP genes, further indicating the specific association of SFRP1 methylation with this AML subtype. The apparent association between methylation of Wnt modulators and specific cytogenetic subtypes might also contribute to the discordant prognostic impacts of Wnt modulator methylation in AML patients due to different patient selection.
While Wnt signaling is critically involved in normal and malignant hematopoiesis, the role of individual SFRP genes in these processes has remained unclear. It was suggested that these genes might have different roles as indicated by differential expression patterns in hematopoietic cells. 40 In particular, SFRP1 expression was recently found to be downregulated in patients with AML, myelodysplastic syndrome, and acute lymphoblastic leukemia. 41 In this study, we found that SFRP1 but not other SFRP genes was a transcriptional repression target of the RUNX1-ETO fusion protein in AML. The repression was mediated through direct binding of RUNX1-ETO to a consensus RUNX site on the SFRP1 promoter. Our ChIP analyses also suggested that RUNX1-ETO recruited DNMTs and HDAC1 to the SFRP1 promoter, implying multiple mechanisms of SFRP1 silencing by the fusion protein. Indeed, previous studies have also demonstrated synergistic upregulation of SFRP1 expression by HDAC and DNMT inhibitors. 42 The recruitment of DNMTs by RUNX1-ETO to the SFRP1 promoter supported our observations of preferential methylation of the SFRP1 promoter in t(8;21)-AML. Nonetheless, the precise mechanism of epigenetic regulation of SFRP1 by RUNX1-ETO remains to be
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From elucidated. Although RUNX1-ETO is generally thought to repress genes that are activated by RUNX1, forced expression of wild-type RUNX1 did not activate but rather mildly repressed the SFRP1 promoter. Our findings further support the model that t(8;21) interferes with normal RUNX1 activity by converting RUNX1 into a constitutive repressor. 43 Previous studies showed that SFRP1 can modulate canonical and noncanonical Wnt signaling both positively and negatively. [44] [45] [46] [47] Here we demonstrated that SFRP1 selectively Consistently, earlier studies have also demonstrated an important role of the β-catenin-dependent TCF and LEF signaling in the growth of this specific subtype of leukemia cells. 10 On the other hand, treatment of Kasumi-1 cells with SFRP1 alone did not affect apoptosis, which could be readily induced by the HDAC inhibitor trichostatin A (our unpublished data, February 2011).
Worthy of note is that this cell line also exhibits epigenetic silencing of other Wnt regulators such as SFRP5 and whether concomitant re-expression of these genes is required to induce cell death remains to be addressed. These observations also raise the need of using patient samples for further characterization of SFRP1 actions in t(8;21)-AML.
In conclusion, we demonstrated that SFRP1 was a direct target of the t(8;21) fusion protein in AML. Unlike Wnt activation via plakoglobin induction that is shared by other AML fusion proteins, 10 our findings of transcriptional repression of SFRP1 by RUNX1-ETO represent a specific mechanism by which the fusion protein perturbs the canonical Wnt pathway. Also, our 
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